论文部分内容阅读
[目的]评价胸腔内热循环灌注化疗治疗晚期非小细胞肺癌合并顽固性恶性胸腔积液的有效性。[方法]41例晚期非小细胞肺癌合并顽固性胸腔积液,按照治疗方式不同分为A、B两组。A组17例患者行肺叶切除或肺楔形切除减负手术,并行胸腔内热循环灌注化疗;B组24例行单纯胸腔内热灌注化疗。[结果]全组无围手术期死亡、心衰或肺水肿发生。A组胸腔积液有效控制率达94.12%,B组为95.83%。2.44%患者发生3级以上白细胞减少,重度恶心发生率为2.44%,7.32%～17.07%的患者表现为Ⅰ～Ⅱ度毒性反应。A、B组患者1年生存率分别为64.71%和37.50%。[结论]胸腔内热循环灌注化疗治疗晚期非小细胞肺癌合并恶性胸腔积液安全有效。
[Objective] To evaluate the effectiveness of intrathoracic thermal perfusion chemotherapy in the treatment of advanced non-small cell lung cancer with refractory malignant pleural effusion. [Method] 41 cases of advanced non-small cell lung cancer with refractory pleural effusion, divided into A and B groups according to different treatment methods. A group of 17 patients underwent lobectomy or pulmonary wedge resection and subtraction surgery, concurrent intrathoracic thermal cycle perfusion chemotherapy; B group of 24 patients underwent simple intrathoracic thermal perfusion chemotherapy. [Results] The whole group had no perioperative death, heart failure or pulmonary edema. Group A pleural effusion effective control rate of 94.12%, B group was 95.83%. 2.44% patients had grade 3 leukopenia, the incidence of severe nausea was 2.44%, 7.32% ~ 17.07% of patients showed Ⅰ ~ Ⅱ degree toxicity. The 1-year survival rates of patients in group A and B were 64.71% and 37.50% respectively. [Conclusion] Intrathoracic thermal perfusion chemotherapy is safe and effective in the treatment of advanced non-small cell lung cancer with malignant pleural effusion.